No adjustment within stated limits
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Tamsulosin capsules require no renal adjustment in the studied population. Patients with CrCl below 10 mL/min have not been studied. Limits and monitoring Check orthostatic symptoms. The renal statement does not establish a dialysis regimen. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 6, posted Jul 29, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Renal impairment, including hemodialysis, does not require a dose change for tedizolid phosphate. Limits and monitoring Select the regimen for the labeled indication and patient age. The renal statement does not extend approved treatment duration. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 34, posted Mar 16, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Insufficient evidence
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding CrCl below 10 mL/min, including ESRD on HD, has insufficient evidence for a specific telavancin dose. Other renal categories have defined label adjustments. Limits and monitoring Check the indication and renal warnings, including the mortality warning in HABP/VABP patients with baseline CrCl at or below 50 mL/min. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 6, posted Dec 23, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure CLcr, mL/min/m2 as printed in the label Renal action or finding The temozolomide label specifies no renal reduction for CLcr 36-130 mL/min/m2. A dose has not been established below 36 or in ESRD on dialysis. Limits and monitoring The label prints mL/min/m2 for this threshold. Preserve its stated convention when interpreting the range. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 40, posted Mar 04, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The temsirolimus label specifies no renal dose reduction. Limits and monitoring Hemodialysis has not been studied. This statement concerns intravenous temsirolimus. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 39, posted Dec 29, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding For the adult 300 mg TDF tablet, increase the interval when CrCl falls below 50 mL/min. The 50-80 mL/min group needs no renal adjustment. Limits and monitoring No regimen is established below 10 mL/min without HD or for children with renal impairment. Use the separate HD row and monitor renal toxicity. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 31, posted Feb 24, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding In five patients with CrCl below 30 mL/min, teriparatide exposure rose by 73% and half-life rose by 77%. Limits and monitoring The small pharmacokinetic study does not establish an adjustment or resolve the effects on renal metabolic bone disease. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 44, posted Aug 19, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Very little thalidomide is excreted unchanged in urine, so renal impairment is expected to have limited influence on exposure. Limits and monitoring This is an exposure prediction. It does not establish dialysis removal or supplementation. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 26, posted Oct 26, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding At CrCl 30-59 mL/min, exposure to thiotepa and its active metabolite TEPA may increase. Limits and monitoring Monitor toxicity. The finding does not supply a fixed percentage reduction. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 30, posted Feb 16, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Renal dysfunction alone does not require a ticagrelor dose change. Dialysis efficacy and safety outcomes were not established in the pivotal studies. Limits and monitoring Exposure and platelet inhibition observations in HD do not establish an outcome benefit in ESRD. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 56, posted Aug 07, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding No renal reduction is needed for IV tigecycline, including in patients receiving hemodialysis. Limits and monitoring Review the indication, boxed mortality warning and separate hepatic dosing instructions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 50, posted Nov 19, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Severe renal impairment alone does not require dose reduction. When tinidazole is taken before HD on the same day, give another half of the recommended dose after the session. Limits and monitoring The supplement applies to the timing described. The severe-impairment PK study used CrCl below 22 mL/min. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 9, posted Dec 28, 2021 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
